GlaxoSmithKline plc announces changes to its Board
GlaxoSmithKline plc (the 'Company') today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company's Annual General Meeting on 7 May 2015 ('AGM'). He will be succeeded by Sir Philip Hampton with effect from the end of the AGM.
Sir Philip joined GSK's Board as an independent Non-Executive Director on 1 January 2015, and will become Deputy Chairman on 1 April 2015. Sir Philip chairs the Company's Nominations Committee. He will remain Chairman of RBS until 31 August 2015.
In addition, Tom de Swaan, independent Non Executive Director, is not seeking re-election to the Board at the AGM. He has been a Board member for 9 years and is currently Chairman of the Remuneration Committee and a member of the Audit & Risk Committee (of which he was previously Chairman), and the Nominations Committee. A successor for Mr de Swaan as Chairman of the Remuneration Committee will be announced in due course.
Jing Ulrich has decided not to stand for re-election to the Board at the AGM.
V A Whyte
Company Secretary
26 February 2015
Notes
With effect from the end of the Company's AGM on 7 May 2015, the composition of the Board of GSK will be as follows:
Sir Philip Hampton Non-Executive Chairman
Sir Deryck Maughan Senior Independent Non-Executive Director
Sir Andrew Witty Chief Executive Officer
Simon Dingemans Chief Financial Officer
Dr Moncef Slaoui Executive Director, Chairman, Global Vaccines
Professor Sir Roy Anderson Independent Non-Executive Director
Dr Stephanie Burns Independent Non-Executive Director
Stacey Cartwright Independent Non-Executive Director
Lynn Elsenhans Independent Non-Executive Director
Judy Lewent Independent Non-Executive Director
Dr Daniel Podolsky Independent Non-Executive Director
Urs Rohner Independent Non-Executive Director
Hans Wijers Independent Non-Executive Director